immunomedics
announces
fda
orphan
drug
designation
adult
pediatric
glioblastoma
morris
plains
globe
newswire
immunomedics
nasdaq
immu
immunomedics
company
leading
biopharmaceutical
company
area
conjugates
today
announced
office
orphan
products
development
food
drug
administration
fda
granted
trodelvy
sacituzumab
orphan
status
treatment
adult
pediatric
patients
glioblastoma
glioblastoma
aggressive
cancer
large
unmet
need
orphan
drug
designation
important
milestone
immunomedics
strive
broaden
clinical
utility
trodelvy
said
loretta
itri
chief
medical
officer
immunomedics
reported
recent
esmo
congress
trodelvy
shown
encouraging
activity
study
brain
cancers
including
partial
responses
small
cohorts
patients
brain
metastasis
breast
cancer
recurrent
glioblastoma
look
forward
continuing
evaluation
trodelvy
potential
improve
prognosis
underserved
patient
orphan
drug
status
granted
fda
support
development
drugs
biologics
underserved
patient
populations
rare
disorders
affect
fewer
people
orphan
drug
designation
qualifies
company
various
development
incentives
including
tax
credits
qualified
clinical
studies
waiver
new
drug
application
fee
designated
period
market
exclusivity
following
approval
trodelvy
trodelvy
sacituzumab
lead
product
advanced
program
immunomedics
unique
conjugate
adc
platform
trodelvy
adc
directed
protein
expressed
many
solid
cancers
trodelvy
binds
delivers
drug
kill
cancer
cells
immunomedics
extensive
development
program
trodelvy
including
multiple
ongoing
studies
breast
cancer
metastatic
urothelial
cancer
hormone
human
epidermal
growth
factor
receptor
metastatic
breast
cancer
metastatic
cell
lung
cancer
either
monotherapy
combination
agents
visit
https
information
glioblastoma
according
national
cancer
institute
nci
estimated
american
diagnosed
brain
nervous
system
cancer
people
die
disease
among
numerous
brain
tumor
types
glioblastoma
gbm
aggressive
median
survival
pfs
median
overall
survival
os
diagnosis
months
months
respectively
reported
clinical
patients
recurrent
gbm
chemotherapy
regimens
associated
overall
response
rates
pfs
median
os
immunomedics
immunomedics
leader
conjugate
adc
technology
committed
help
transform
lives
people
cancers
proprietary
adc
platform
centers
using
novel
linker
require
enzyme
release
payload
deliver
active
drug
inside
tumor
cell
tumor
microenvironment
thereby
producing
bystander
effect
trodelvy
lead
adc
first
adc
fda
approved
treatment
people
metastatic
breast
cancer
also
first
adc
additional
information
company
please
visit
website
https
information
website
however
form
part
press
release
cautionary
note
regarding
statements
release
addition
historical
information
may
contain
statements
made
pursuant
private
securities
litigation
reform
act
statements
including
statements
regarding
expectations
achieving
full
fda
approval
based
confirmatory
data
trodelvy
company
development
trodelvy
additional
indications
clinical
trials
including
funding
therefor
anticipated
patient
enrollment
trial
outcomes
timing
associated
costs
regulatory
applications
related
timelines
including
filing
approval
timelines
blas
bla
supplements
arrangements
forecasts
future
operating
results
potential
collaborations
capital
raising
activities
timing
bringing
product
candidate
market
involve
significant
risks
uncertainties
actual
results
could
differ
materially
expressed
implied
herein
factors
could
cause
differences
include
limited
company
reliance
relationships
outsourcing
arrangements
example
connection
manufacturing
logistics
distribution
sales
marketing
may
always
full
control
including
failure
third
parties
company
dependent
meet
company
business
operational
needs
investigational
commercial
products
comply
company
agreements
laws
regulations
impact
company
company
ability
meet
compliance
obligations
topics
including
limited
product
quality
product
distribution
supply
chain
requirements
promotional
marketing
compliance
imposition
significant
regulatory
requirements
products
including
requirement
confirmatory
clinical
study
failure
maintain
obtain
full
regulatory
approval
company
products
received
due
failure
satisfy
regulatory
requirements
submission
sufficient
data
confirmatory
clinical
uncertainties
inherent
research
development
safety
efficacy
concerns
related
company
products
product
uncertainties
rate
degree
market
acceptance
products
product
candidates
inability
create
effective
direct
sales
marketing
infrastructure
partner
third
parties
offer
infrastructure
distribution
company
products
product
candidates
inaccuracies
company
estimates
size
potential
markets
company
products
product
candidates
limitations
regulators
proposed
treatment
population
company
products
product
decisions
regulatory
authorities
regarding
labeling
matters
could
affect
availability
commercial
potential
company
products
product
candidates
company
dependence
business
collaborations
availability
required
financing
capital
markets
sources
acceptable
terms
order
develop
products
finance
operations
new
product
development
including
clinical
trials
outcome
regulatory
requirements
actions
risk
collaborators
may
unable
secure
regulatory
approval
market
drug
candidates
risks
relating
pandemic
around
world
risks
associated
litigation
company
may
become
party
including
cost
potential
reputational
damage
resulting
litigation
loss
key
personnel
competitive
risks
marketed
products
company
ability
repay
outstanding
indebtedness
required
well
risks
discussed
company
filings
securities
exchange
commission
company
obligation
company
expressly
disclaims
obligation
update
alter
statements
whether
result
new
information
future
events
otherwise
references
https
statfacts
html
accessed
october
stupp
r
mason
wp
van
den
bent
mj
et
al
european
organisation
research
treatment
cancer
brain
tumor
radiotherapy
groups
national
cancer
institute
canada
clinical
trials
group
radiotherapy
plus
concomitant
adjuvant
temozolomide
glioblastoma
n
engl
j
med
gilbert
mr
dignam
jj
armstrong
ts
et
al
randomized
trial
bevacizumab
newly
diagnosed
glioblastoma
n
engl
j
med
gilbert
mr
wang
aldape
kd
et
al
temozolomide
newly
diagnosed
glioblastoma
randomized
phase
iii
clinical
trial
j
clin
oncol
chinot
ol
wick
w
mason
w
et
al
bevacizumab
plus
newly
diagnosed
glioblastoma
n
engl
j
med
wong
et
hess
kr
gleason
mj
et
al
outcomes
prognostic
factors
recurrent
glioma
patients
enrolled
onto
phase
ii
clinical
trials
clin
oncol
van
den
bent
mj
brandes
aa
rampling
r
et
al
randomized
phase
ii
trial
erlotinib
versus
temozolomide
carmustine
recurrent
glioblastoma
eortc
brain
tumor
group
study
clin
oncol
batchelor
tt
mulholland
p
neyns
b
et
al
phase
iii
randomized
trial
comparing
efficacy
cediranib
monotherapy
combination
lomustine
versus
lomustine
alone
patients
recurrent
glioblastoma
clin
oncol
wick
w
puduvalli
vk
chamberlain
mc
et
al
phase
iii
study
enzastaurin
compared
lomustine
treatment
recurrent
intracranial
glioblastoma
clin
oncol
taal
w
oosterkamp
hm
walenkamp
ame
et
al
bevacizumab
lomustine
versus
combination
bevacizumab
plus
lomustine
patients
recurrent
glioblastoma
belob
trial
randomised
controlled
phase
trial
lancet
oncol
information
chau
cheng
ccheng
media
inquiries
darren
opland
darren
